You have free access to this content

Cancer

Cover image for Cancer

15 March 2004

Volume 100, Issue 6

Pages 1107–1326

  1. Commentaries

    1. Top of page
    2. Commentaries
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      The ethics of reporting and disseminating results of clinical research trials (pages 1107–1109)

      Jeffrey G. Bell, Mark Brady and Larry J. Copeland

      Version of Record online: 12 FEB 2004 | DOI: 10.1002/cncr.20067

      A frank and ethical discussion of results from clinical trials should provide patients with all data that may influence the patient's decision regarding treatment options. Such discussion should include the best available estimate of the treatment benefits as well as a description of the anticipated toxicities.

  2. Original Articles

    1. Top of page
    2. Commentaries
    3. Original Articles
    4. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis (pages 1110–1122)

      Xishan Hao, Baocun Sun, Limei Hu, Harri Lähdesmäki, Valerie Dunmire, Yumei Feng, Shi-Wu Zhang, Huamin Wang, Chunlei Wu, Hua Wang, Gregory N. Fuller, W. Fraser Symmans, Ilya Shmulevich and Wei Zhang

      Version of Record online: 6 FEB 2004 | DOI: 10.1002/cncr.20095

      • original image
      • original image
      • original image

      Gene expression profiling and tissue microarray validation of matched primary breast carcinoma and lymph node metastasis tissue samples revealed molecular events in the metastatic process.

    2. Endocrine Disease
      You have free access to this content
      Follicular thyroid carcinoma: Histology and prognosis (pages 1123–1129)

      Alessandra D'Avanzo, Patrick Treseler, Philip H. G. Ituarte, Mariwil Wong, Leanne Streja, Francis S. Greenspan, Allan E. Siperstein, Quan-Yang Duh and Orlo H. Clark

      Version of Record online: 13 FEB 2004 | DOI: 10.1002/cncr.20081

      • original image
      • original image
      • original image

      The authors have documented that the extent of invasion in patients with follicular thyroid carcinoma (capsular invasion only, angioinvasion with or without capsular invasion, or widespread invasion) influences prognosis. They recommend classifying follicular thyroid carcinomas as minimally invasive, moderately invasive, or widely invasive.

    3. Gastrointestinal Tract
      You have free access to this content
      Expression of regenerating gene I in gastric adenocarcinomas : Correlation with tumor differentiation status and patient survival (pages 1130–1136)

      Dipok Kumar Dhar, Jun Udagawa, Shunji Ishihara, Hiroki Otani, Yoshikazu Kinoshita, Shin Takasawa, Hiroshi Okamoto, Hirofumi Kubota, Toshiyuki Fujii, Mitsuo Tachibana and Naofumi Nagasue

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20097

      • original image
      • original image
      • original image

      Determination of regenerating gene I (REG) expression may help to identify patients with aggressive gastric tumors with worse prognosis. Identification of REG expression may be used to tailor appropriate therapy for patients with gastric carcinoma and could be a useful target for therapeutic intervention.

    4. Genitourinary Disease
      You have free access to this content
      The impact of testicular carcinoma and its treatment on sperm DNA integrity (pages 1137–1144)

      Olof Ståhl, Jakob Eberhard, Katarina Jepson, Marcello Spano, Magdalena Cwikiel, Eva Cavallin-Ståhl and Aleksander Giwercman

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20068

      • original image
      • original image

      Sperm DNA integrity was investigated by means of sperm chromatin structure assay in 74 patients with testicular carcinoma. A decrease in the DNA fragmentation index was observed after three or more cycles of chemotherapy whereas it increased transiently after radiotherapy. Postorchiectomy, this value did not differ between patients and controls.

    5. Gynecologic Oncology
      You have free access to this content
      Restaging surgery for women with borderline ovarian tumors : Results of a French multicenter study (pages 1145–1151)

      Raffaèle Fauvet, Joëlle Boccara, Charlotte Dufournet, Emmanuel David-Montefiore, Christophe Poncelet and Emile Daraï

      Version of Record online: 20 FEB 2004 | DOI: 10.1002/cncr.20098

      • original image

      In a retrospective French multicenter study, 54 of 360 women with borderline ovarian tumors underwent disease restaging. Women who initially were diagnosed with Stage IA disease and who had serous borderline tumors or underwent cystectomy appeared to derive the most benefit from restaging. Nonetheless, no difference in recurrence rate was observed between women who underwent restaging and those who did not. Thus, the indications for restaging surgery remain controversial.

    6. You have free access to this content
      Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? (pages 1152–1161)

      Rong-Yu Zang, Zi-Ting Li, Jie Tang, Xi Cheng, Shu-Mo Cai, Zhi-Yi Zhang and Nelson N. Teng

      Version of Record online: 20 FEB 2004 | DOI: 10.1002/cncr.20106

      • original image
      • original image
      • original image
      • original image

      Secondary cytoreductive surgery (SCR) was feasible and efficacious in patients with epithelial ovarian carcinoma who had tumors that recurred after a progression-free interval ⩾ 3 months. A survival benefit was provided by optimal SCR, particularly when surgery was supported by multiple courses of salvage chemotherapy.

    7. Head and Neck Disease
      You have free access to this content
      Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma (pages 1162–1170)

      Jian-Yong Shao, Yu-Hong Li, Hong-Yi Gao, Qiu-Liang Wu, Nian-Ji Cui, Li Zhang, Gang Cheng, Li-Fu Hu, Ingemar Ernberg and Yi-Xin Zeng

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20099

      • original image
      • original image
      • original image

      The authors compared plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/viral capsid antigen antibody titers in patients with nasopharyngeal carcinoma (NPC) in different clinical stages and found that the plasma EBV DNA level was a more sensitive and specific marker for the early diagnosis, staging, and monitoring of metastasis and recurrence in patients with NPC.

    8. You have free access to this content
      Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? (pages 1171–1178)

      Adam S. Garden, Joshua A. Asper, William H. Morrison, Naomi R. Schechter, Bonnie S. Glisson, Merrill S. Kies, Jeffrey N. Myers and K. Kian Ang

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20069

      • original image
      • original image
      • original image
      • original image

      The authors conducted a retrospective study of 299 patients with Stage III or IV oropharyngeal carcinoma who had small primary tumors and lymphadenopathy and who underwent radiotherapy (with or without surgery). These patients had high rates of disease control and, specifically, locoregional control. Therefore, the addition of concurrent chemotherapy may not expand the therapeutic window.

    9. Hematologic Malignancies
      You have free access to this content
      Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen (pages 1179–1185)

      Mary Ann Weiser, Maria E. Cabanillas, Marina Konopleva, Deborah A. Thomas, Sherry A. Pierce, Carmen P. Escalante, Hagop M. Kantarjian and Susan M. O'Brien

      Version of Record online: 12 FEB 2004 | DOI: 10.1002/cncr.20071

      • original image
      • original image
      • original image
      • original image

      Hyperglycemia (a glucose level ≥ 200 mg/dL) is reported to occur in approximately 37% of patients during induction chemotherapy for acute lymphoblastic leukemia with a chemotherapy regimen comprised of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone. Patients with hyperglycemia have a shorter duration of complete remission, experience an increase in overall mortality, and are at an increased risk for developing complicated infections.

    10. You have free access to this content
      Thalidomide for patients with recurrent lymphoma (pages 1186–1189)

      Barbara Pro, Anas Younes, Maher Albitar, Nam H. Dang, Felipe Samaniego, Jorge Romaguera, Peter McLaughlin, Fredrick B. Hagemeister, Maria A. Rodriguez, Marilyn Clemons and Fernando Cabanillas

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20070

      • original image

      Nineteen patients with recurrent or refractory lymphoma who had undergone a median of 5 previous treatment regimens were treated with escalating doses of thalidomide (200–800 mg per day). Thalidomide exhibited limited single-agent activity, as one patient with evidence of recurrent gastric mucosa–associated lymphoid tissue lymphoma achieved a complete response, and three patients achieved stable disease.

    11. Lung Disease
      You have free access to this content
      Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma (pages 1190–1198)

      Kenzo Hiroshima, Akira Iyoda, Kiyoshi Shibuya, Yukiko Haga, Tetsuya Toyozaki, Toshihiko Iizasa, Toshinori Nakayama, Takehiko Fujisawa and Hidemi Ohwada

      Version of Record online: 20 FEB 2004 | DOI: 10.1002/cncr.20108

      • original image
      • original image
      • original image
      • original image
      • original image

      Allelic losses at 3p occurred both in large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), but not in classic large cell carcinoma, at an early stage of carcinogenesis. The p16 gene abnormality occurred frequently in LCNEC, but not in SCLC.

    12. Neuro-Oncology
      You have free access to this content
      Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma (pages 1199–1207)

      Peter Hau, Klaus Fabel, Ulrike Baumgart, Petra Rümmele, Oliver Grauer, Annekatrin Bock, Christopher Dietmaier, Wolfgang Dietmaier, Jörg Dietrich, Christine Dudel, Franz Hübner, Tanya Jauch, Elisabeth Drechsel, Ingo Kleiter, Cäcile Wismeth, Anton Zellner, Alexander Brawanski, Andreas Steinbrecher, Jörg Marienhagen and Ulrich Bogdahn

      Version of Record online: 6 FEB 2004 | DOI: 10.1002/cncr.20073

      • original image
      • original image

      Pegylated liposomal doxorubicin administered alone or in combination with tamoxifen represents a safe and moderately effective treatment regimen for patients with recurrent high-grade glioma. No correlation between clinical response and expression of tumor resistance genes was detectable.

    13. You have free access to this content
      Frequency and risk factors for meningioma in clinically healthy 75-year-old patients : Results of the Transdanube Ageing Study (VITA) (pages 1208–1212)

      Wolfgang Krampla, Stephan Newrkla, Wolfgang Pfisterer, Susanne Jungwirth, Peter Fischer, Thomas Leitha, Walter Hruby and Karl Heinz Tragl

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20088

      Clinically quiescent meningiomas in the elderly female population were reported to be more common than was believed to be the case to date. Known and influenceable risk factors were found to be less important than age and gender.

    14. You have free access to this content
      Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme (pages 1213–1220)

      Marc C. Chamberlain and Denice D. Tsao-Wei

      Version of Record online: 4 FEB 2004 | DOI: 10.1002/cncr.20072

      • original image

      In the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme, CYC exhibited modest efficacy with acceptable toxicity.

    15. You have free access to this content
      A multicenter study of the prognosis and treatment of adult brain ependymal tumors (pages 1221–1229)

      Michele Reni, Alba Ariela Brandes, Vittorio Vavassori, Giovanna Cavallo, Federica Casagrande, Francesca Vastola, Alessandro Magli, Alberto Franzin, Umberto Basso and Eugenio Villa

      Version of Record online: 4 FEB 2004 | DOI: 10.1002/cncr.20074

      • original image
      • original image

      Data from a large retrospective series of adult ependymal tumors are reported. Patient age < 40 years and infratentorial tumor location were found to be predictive of a more favorable outcome, and radiotherapy use was found to be associated with a clear trend (albeit one of borderline statistical significance) toward longer overall survival and with a significant trend toward improved failure-free survival.

    16. You have free access to this content
      The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era : An analysis of 258 patients (pages 1230–1237)

      Andrey Korshunov, Andrey Golanov, Regina Sycheva and Valery Timirgaz

      Version of Record online: 30 JAN 2004 | DOI: 10.1002/cncr.20075

      • original image
      • original image
      • original image

      An application of the uniform diagnostic criteria for ependymoma grading highlights the key role of tumor histology for the clinical outcome in a cohort of patients with ependymoma who were treated in the microsurgical era.

    17. Discipline

      Clinical Trials
      You have free access to this content
      Dissemination of information on legislative mandates and consensus-based programs addressing payment of the costs of routine care in clinical trials through the World Wide Web (pages 1238–1245)

      Andrew M. Kelahan

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20066

      State laws and consensus-based programs have been enacted by a number of states and private and government-sponsored health plans to ensure payment of the costs of routine care in clinical trials. World Wide Web sites of cancer research institutions organizations and patient advocate groups are prime repositories for information on access and delivery of healthcare services but rarely present enough information to fully inform patients and their surrogates about clinical trials and rarely overcome barriers to participation.

    18. Diagnostic Imaging
      You have free access to this content
      Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors (pages 1246–1256)

      A. Aria Tzika, Loukas G. Astrakas, Maria K. Zarifi, David Zurakowski, Tina Young Poussaint, Liliana Goumnerova, Nancy J. Tarbell and Peter McL. Black

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20096

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Magnetic resonance spectroscopic imaging assisted by relative tumor blood volume measurement provides in vivo biomarkers that are useful in predicting tumor progression in children with brain tumors.

    19. Medical Oncology
      You have free access to this content
      Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site (pages 1257–1261)

      Damien Pouessel, Stéphane Culine, Catherine Becht, Marc Ychou, Gilles Romieu, Michel Fabbro, Didier Cupissol and Frédéric Pinguet

      Version of Record online: 10 FEB 2004 | DOI: 10.1002/cncr.20100

      • original image

      A median survival of 10 months was observed in 36 patients with carcinomas of an unknown primary site who were treated with a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel.

    20. Radiation Oncology
      You have free access to this content
      Quality of colon carcinoma pathology reporting : A process of care study (pages 1262–1267)

      Jeffrey T. Wei, Eric A. Miller, John T. Woosley, Christopher F. Martin and Robert S. Sandler

      Version of Record online: 4 FEB 2004 | DOI: 10.1002/cncr.20090

      Pathology reports communicated well most of the pertinent findings from surgically resected colon carcinoma specimens. Omissions of some critical characteristics did occur, however, and significant variability in reporting existed based on lab affiliation and hospital case volume.

    21. Pediatric Oncology
      You have free access to this content
      Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma (pages 1268–1275)

      Scott M. Bradfield, James G. Douglas, Douglas S. Hawkins, Jean E. Sanders and Julie R. Park

      Version of Record online: 12 FEB 2004 | DOI: 10.1002/cncr.20091

      Postautologous hematopoietic stem cell transplantation consolidation radiotherapy of 2100 centigrays given to the primary site, using postchemotherapy volumes, and to initial metastatic sites in patients with high-risk neuroblastoma provides excellent local and metastatic disease control. Reversible hematopoietic and gastrointestinal toxicity occurs in the majority of patients.

    22. Psychological Oncology
      You have free access to this content
      Optimism and survival in lung carcinoma patients (pages 1276–1282)

      Penelope Schofield, David Ball, Jennifer G. Smith, Ron Borland, Peter O'Brien, Sidney Davis, Ian Olver, Gail Ryan and David Joseph

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20076

      • original image
      • original image

      In this study of optimism and survival in 179 lung carcinoma patients, no association was found between pretreatment optimism and progression-free or overall survival. It was concluded that simplistically encouraging patients to “be positive” simply may add to the burden of having cancer while providing little survival benefit, at least in the case of lung cancer.

    23. Radiation Oncology
      You have free access to this content
      Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era : What should we expect? (pages 1283–1292)

      Deepak Khuntia, Chandana A. Reddy, Arul Mahadevan, Eric A. Klein and Patrick A. Kupelian

      Version of Record online: 13 FEB 2004 | DOI: 10.1002/cncr.20093

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In the PSA era, the most significant therapeutic factor impacting biochemical recurrence-free survival rates in patients with localized prostate carcinoma after external-beam radiotherapy is radiation dose, rather than use of androgen-deprivation therapy or radiation technique.

    24. Pathology
      You have free access to this content
      Estimation of an optimal radiotherapy utilization rate for melanoma : A review of the evidence (pages 1293–1301)

      Geoff Delaney, Michael Barton and Susannah Jacob

      Version of Record online: 9 FEB 2004 | DOI: 10.1002/cncr.20092

      • original image
      • original image

      The authors developed an evidence-based benchmark for the proportion of patients with melanoma who should receive radiotherapy at least once by reviewing treatment guidelines on melanoma and merging the indications for radiotherapy with epidemiologic data. The resulting optimal radiotherapy utilization rate for melanoma was then compared with radiotherapy utilization rates recorded in clinical practice.

    25. Symptom Control and Palliative Care
      You have free access to this content
      A randomized clinical trial of energy conservation for patients with cancer-related fatigue (pages 1302–1310)

      Andrea M. Barsevick, William Dudley, Susan Beck, Carole Sweeney, Kyra Whitmer and Lillian Nail

      Version of Record online: 20 FEB 2004 | DOI: 10.1002/cncr.20111

      In a randomized clinical trial, an energy conservation activity management (ECAM) intervention for fatigue reduction was compared with a control intervention focused on nutrition. The results demonstrated a statistically significant difference over time between the intervention groups favoring the ECAM intervention.

    26. Translational Research
      You have free access to this content
      Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice (pages 1311–1323)

      Stephanie Cobb, Thomas Wood, Jeffrey Ceci, Andrea Varro, Marco Velasco and Pomila Singh

      Version of Record online: 20 FEB 2004 | DOI: 10.1002/cncr.20094

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In the current report, the authors describe for the first time the generation of transgenic mice that overexpress either wild-type or mutant progastrin in an intestine-specific manner. Mutant mice were found to be positive for ‘physiologic’ concentrations of progastrin (< 1 nM to 5 nM). Both forms of progastrin were found to have potent stimulatory effects on colon carcinogenesis in response to azoxymethane. These findings highlight the potential increased risk of colon carcinogenesis for patients with hypergastrinemia who are known to have progastrin levels ranging from 0.1 nM to > 1.0 nM.

  3. Correspondence

    1. Top of page
    2. Commentaries
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (pages 1325–1326)

      Linda S. Elting, Scott B. Cantor and Edward B. Rubenstein

      Version of Record online: 4 FEB 2004 | DOI: 10.1002/cncr.20103

SEARCH

SEARCH BY CITATION